Primary xenografts of human prostate tissue as a model to study angiogenesis induced by reactive stroma by Montecinos, Viviana P, Godoy, Alejandro, Hinklin, Jennifer, Vethanayagam, R Robert, Smith, Gary J

Get full text

Discovery of Pyrazolopyrazines as Selective, Potent, and Mutant-Active MET Inhibitors with Intracranial Efficacy by Bumpers, Quinn A., Pipal, Robert W., Benz-Weeden, Anna M., Brewster, James T., Cook, Adam, Crooks, Amy L., Cruz, Cole, Dwulet, Natalie C., Gaudino, John J., Golec, Daniel, Harrison, Jacqueline A., Hartley, Dylan P., Hassanien, Sherif H., Hicken, Erik J., Kahn, Dean, Laird, Ellen R., Lemieux, Christine, Lewandowski, Nicholas, McCown, Joseph, McDonald, Matthew G., McNulty, Oren, Mou, Tung-Chung, Nguyen, Phong, Oko, Lauren, Opie, Lisa Pieti, Otten, Jennifer, Peck, Spencer C., Polites, Viktor C., Randall, Samuel D., Rosen, Rachel Z., Savechenkov, Pavel, Simpson, Helen, Singh, Anurag, Sparks, Drew, Wickersham, Kyle, Wollenberg, Lance, Wong, Christina E., Wong, Jim, Wu, Wen-I, Elsayed, Mohamed S. A., Hinklin, Ronald J., Tang, Tony P.

Get full text

Discovery of 5‑Azaquinoxaline Derivatives as Potent and Orally Bioavailable Allosteric SHP2 Inhibitors by Elsayed, Mohamed S. A., Blake, James F., Boys, Mark L., Brown, Eric, Chapsal, Bruno D., Chicarelli, Mark J., Cook, Adam W., Fell, Jay B., Fischer, John P., Hanson, Lauren, Lemieux, Christine, Martinson, Matthew C., McCown, Joseph, McNulty, Oren T., Mejia, Macedonio J., Neitzel, Nickolas A., Otten, Jennifer N., Rodriguez, Martha E., Wilcox, Daniel, Wong, Christina E., Zhou, Yeyun, Hinklin, Ronald J.

Get full text

Identification of the Clinical Development Candidate MRTX849 , a Covalent KRAS G12C Inhibitor for the Treatment of Cancer by Fell, Jay B, Fischer, John P, Baer, Brian R, Blake, James F, Bouhana, Karyn, Briere, David M, Brown, Karin D, Burgess, Laurence E, Burns, Aaron C, Burkard, Michael R, Chiang, Harrah, Chicarelli, Mark J, Cook, Adam W, Gaudino, John J, Hallin, Jill, Hanson, Lauren, Hartley, Dylan P, Hicken, Erik J, Hingorani, Gary P, Hinklin, Ronald J, Mejia, Macedonio J, Olson, Peter, Otten, Jennifer N, Rhodes, Susan P, Rodriguez, Martha E, Savechenkov, Pavel, Smith, Darin J, Sudhakar, Niranjan, Sullivan, Francis X, Tang, Tony P, Vigers, Guy P, Wollenberg, Lance, Christensen, James G, Marx, Matthew A

Get full text

Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer by Fell, Jay B, Fischer, John P, Baer, Brian R, Blake, James F, Bouhana, Karyn, Briere, David M, Brown, Karin D, Burgess, Laurence E, Burns, Aaron C, Burkard, Michael R, Chiang, Harrah, Chicarelli, Mark J, Cook, Adam W, Gaudino, John J, Hallin, Jill, Hanson, Lauren, Hartley, Dylan P, Hicken, Erik J, Hingorani, Gary P, Hinklin, Ronald J, Mejia, Macedonio J, Olson, Peter, Otten, Jennifer N, Rhodes, Susan P, Rodriguez, Martha E, Savechenkov, Pavel, Smith, Darin J, Sudhakar, Niranjan, Sullivan, Francis X, Tang, Tony P, Vigers, Guy P, Wollenberg, Lance, Christensen, James G, Marx, Matthew A

Get full text